These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 25186290)

  • 1. Adjuvant stereotactic body radiotherapy following transarterial chemoembolization in patients with non-resectable hepatocellular carcinoma tumours of ≥ 3 cm.
    Jacob R; Turley F; Redden DT; Saddekni S; Aal AK; Keene K; Yang E; Zarzour J; Bolus D; Smith JK; Gray S; White J; Eckhoff DE; DuBay DA
    HPB (Oxford); 2015 Feb; 17(2):140-9. PubMed ID: 25186290
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of Stereotactic Body Radiation Therapy and Transarterial Chemoembolization for Unresectable Medium-Sized Hepatocellular Carcinoma.
    Shen PC; Chang WC; Lo CH; Yang JF; Lee MS; Dai YH; Lin CS; Fan CY; Huang WY
    Int J Radiat Oncol Biol Phys; 2019 Oct; 105(2):307-318. PubMed ID: 31175903
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thermal Ablation Versus Stereotactic Body Radiotherapy After Transarterial Chemoembolization for Inoperable Hepatocellular Carcinoma: A Propensity Score-Weighted Analysis.
    Nabavizadeh N; Jahangiri Y; Rahmani R; Tomozawa Y; Geeratikun Y; Chen Y; Hung A; Degnin C; Farsad K
    AJR Am J Roentgenol; 2021 Sep; 217(3):691-698. PubMed ID: 32997517
    [No Abstract]   [Full Text] [Related]  

  • 4. Long-term survival analysis in combined transarterial embolization and stereotactic body radiation therapy versus stereotactic body radiation monotherapy for unresectable hepatocellular carcinoma >5 cm.
    Su TS; Lu HZ; Cheng T; Zhou Y; Huang Y; Gao YC; Tang MY; Jiang HY; Lian ZP; Hou EC; Liang P
    BMC Cancer; 2016 Nov; 16(1):834. PubMed ID: 27809890
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stereotactic body radiotherapy vs. TACE or RFA as a bridge to transplant in patients with hepatocellular carcinoma. An intention-to-treat analysis.
    Sapisochin G; Barry A; Doherty M; Fischer S; Goldaracena N; Rosales R; Russo M; Beecroft R; Ghanekar A; Bhat M; Brierley J; Greig PD; Knox JJ; Dawson LA; Grant DR
    J Hepatol; 2017 Jul; 67(1):92-99. PubMed ID: 28257902
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stereotactic Body Radiation Therapy as an Alternative to Transarterial Chemoembolization for Hepatocellular Carcinoma.
    Sapir E; Tao Y; Schipper MJ; Bazzi L; Novelli PM; Devlin P; Owen D; Cuneo KC; Lawrence TS; Parikh ND; Feng M
    Int J Radiat Oncol Biol Phys; 2018 Jan; 100(1):122-130. PubMed ID: 29066120
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Pilot Trial Evaluating Stereotactic Body Radiation Therapy to Induce Hyperemia in Combination With Transarterial Chemoembolization for Hepatocellular Carcinoma.
    Sebastian NT; Miller ED; Yang X; Diaz DA; Tan Y; Dowell J; Spain J; Rikabi A; Elliott E; Knopp M; Williams TM
    Int J Radiat Oncol Biol Phys; 2020 Dec; 108(5):1276-1283. PubMed ID: 32712254
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined therapy of transarterial chemoembolization and stereotactic body radiation therapy versus transarterial chemoembolization for ≤5cm hepatocellular carcinoma: Propensity score matching analysis.
    Jun BG; Kim SG; Kim YD; Cheon GJ; Han KH; Yoo JJ; Kim YS; Jeong SW; Jang JY; Lee SH; Park S; Kim HS
    PLoS One; 2018; 13(10):e0206381. PubMed ID: 30379885
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Better survival after stereotactic body radiation therapy following transarterial chemoembolization in nonresectable hepatocellular carcinoma: A propensity score matched analysis.
    Wong TC; Chiang CL; Lee AS; Lee VH; Yeung CS; Ho CH; Cheung TT; Ng KK; Chok SH; Chan AC; Dai WC; Wong FC; Luk MY; Leung TW; Lo CM
    Surg Oncol; 2019 Mar; 28():228-235. PubMed ID: 30851906
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stereotactic body radiation therapy combined with transcatheter arterial chemoembolization for small hepatocellular carcinoma.
    Honda Y; Kimura T; Aikata H; Kobayashi T; Fukuhara T; Masaki K; Nakahara T; Naeshiro N; Ono A; Miyaki D; Nagaoki Y; Kawaoka T; Takaki S; Hiramatsu A; Ishikawa M; Kakizawa H; Kenjo M; Takahashi S; Awai K; Nagata Y; Chayama K
    J Gastroenterol Hepatol; 2013 Mar; 28(3):530-6. PubMed ID: 23216217
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High rate of complete histopathological response in hepatocellular carcinoma patients after combined transarterial chemoembolization and stereotactic body radiation therapy.
    Bauer U; Gerum S; Roeder F; Münch S; Combs SE; Philipp AB; De Toni EN; Kirstein MM; Vogel A; Mogler C; Haller B; Neumann J; Braren RF; Makowski MR; Paprottka P; Guba M; Geisler F; Schmid RM; Umgelter A; Ehmer U
    World J Gastroenterol; 2021 Jun; 27(24):3630-3642. PubMed ID: 34239274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase 2 study of stereotactic body radiotherapy and optional transarterial chemoembolization for solitary hepatocellular carcinoma not amenable to resection and radiofrequency ablation.
    Takeda A; Sanuki N; Tsurugai Y; Iwabuchi S; Matsunaga K; Ebinuma H; Imajo K; Aoki Y; Saito H; Kunieda E
    Cancer; 2016 Jul; 122(13):2041-9. PubMed ID: 27062278
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Local control by salvage stereotactic body radiotherapy for recurrent/residual hepatocellular carcinoma after other local therapies.
    Kibe Y; Takeda A; Tsurugai Y; Eriguchi T
    Acta Oncol; 2020 Aug; 59(8):888-894. PubMed ID: 32216593
    [No Abstract]   [Full Text] [Related]  

  • 14. Superselective transarterial chemoembolization vs hepatic resection for resectable early-stage hepatocellular carcinoma in patients with Child-Pugh class a liver function.
    Hsu KF; Chu CH; Chan DC; Yu JC; Shih ML; Hsieh HF; Hsieh TY; Yu CY; Hsieh CB
    Eur J Radiol; 2012 Mar; 81(3):466-71. PubMed ID: 21376495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of local tumor control in patients with HCC treated with SBRT or TACE: a propensity score analysis.
    Bettinger D; Gkika E; Schultheiss M; Glaser N; Lange S; Maruschke L; Buettner N; Kirste S; Nestle U; Grosu AL; Thimme R; Brunner TB
    BMC Cancer; 2018 Aug; 18(1):807. PubMed ID: 30092781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined Chemoembolization and Radiotherapy Versus Chemoembolization Alone for Hepatocellular Carcinoma Invading the Hepatic Vein or Inferior Vena Cava.
    Alrashidi I; Chu HH; Kim JH; Shim JH; Yoon SM; Kim PH; Gwon DI; Ko HK
    Cardiovasc Intervent Radiol; 2021 Jul; 44(7):1060-1069. PubMed ID: 33745071
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor Size Affects Efficacy of Adjuvant Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma and Microvascular Invasion.
    Liu S; Li H; Guo L; Zhang B; Zhou B; Zhang W; Zhou J; Fan J; Ye Q
    Oncologist; 2019 Apr; 24(4):513-520. PubMed ID: 30552155
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stereotactic body radiation therapy as a salvage treatment for single viable hepatocellular carcinoma at the site of incomplete transarterial chemoembolization: a retrospective analysis of 302 patients.
    Lee S; Jung J; Park JH; Kim SY; Choi J; Lee D; Shim JH; Kim KM; Lim YS; Lee HC; Park HH; Kim JH; Yoon SM
    BMC Cancer; 2022 Feb; 22(1):175. PubMed ID: 35172769
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stereotactic body radiation therapy with or without transarterial chemoembolization for patients with primary hepatocellular carcinoma: preliminary analysis.
    Choi BO; Choi IB; Jang HS; Kang YN; Jang JS; Bae SH; Yoon SK; Chai GY; Kang KM
    BMC Cancer; 2008 Nov; 8():351. PubMed ID: 19038025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stereotactic Radiotherapy after Incomplete Transarterial (Chemo-) Embolization (TAE\TACE) versus Exclusive TAE or TACE for Treatment of Inoperable HCC: A Phase III Trial (NCT02323360).
    Comito T; Loi M; Franzese C; Clerici E; Franceschini D; Badalamenti M; Teriaca MA; Rimassa L; Pedicini V; Poretti D; Solbiati LA; Torzilli G; Ceriani R; Lleo A; Aghemo A; Santoro A; Scorsetti M
    Curr Oncol; 2022 Nov; 29(11):8802-8813. PubMed ID: 36421345
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.